On April 2, 2026, President Trump signed a proclamation imposing a 100% tariff on imported branded pharmaceuticals, a move timed to the anniversary of his original “Liberation Day” trade actions. The number looked like a bombshell: a full doubling of the landed cost of drugs that millions of Americans rely on every day. But within hours of the announcement, trade lawyers and pharmaceutical lobbyists were combing through the fine print and reaching the same conclusion. The 100% rate is a ceiling, not a floor, and the biggest players in the industry already have a clear path around it.
What the proclamation actually says
The document, titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” imposes a 100% ad valorem tariff on imported branded drugs and their active pharmaceutical ingredients. The White House cast it as a national security measure designed to reduce American dependence on foreign supply chains.
But the same text includes significant carve-outs: 0% rates for certain specialty drug categories and, critically, a mechanism that lets entire countries or individual companies qualify for far lower rates. That mechanism traces back to Executive Order 14346, signed in September 2025, which established a formal process for granting tariff relief to countries that have signed or are actively negotiating trade and security agreements with Washington. The executive order appears to authorize 0% tariff determinations for qualifying jurisdictions, though the full scope of its application to pharmaceuticals has not been independently verified beyond the text of the order itself. Any jurisdiction meeting the reciprocity and security conditions in that order could, in principle, secure product-level or country-level relief for its pharmaceutical exports.
The practical effect: the 100% rate falls hardest on companies and countries that decline to negotiate.
Three tiers, three very different outcomes
According to the Associated Press, the proclamation sorts drugmakers into three tiers:
- 0% tariff: Companies that accept most-favored-nation pricing agreements and commit to manufacturing in the United States.
- 20%, escalating to 100% over four years: Companies that begin building U.S. production capacity but have not yet signed a pricing deal.
- 100% immediately: Companies that refuse both paths.
The structure turns the tariff into a negotiating lever. Consider Novo Nordisk, which operates a large-scale manufacturing campus in Clayton, North Carolina, and has publicly discussed expanding U.S. production of its blockbuster obesity drug Wegovy and its insulin portfolio. A company with that kind of domestic footprint is well positioned to negotiate toward the lowest tier. A smaller European biotech running a single plant in Basel with no American operations faces a much steeper climb.
The EU agreement that changes the math
For European drugmakers specifically, a pre-existing deal reshapes the landscape. A joint statement from the U.S. Department of Commerce describes a broad framework governing trade between the U.S. and the EU. The agreement addresses tariff ceilings on EU-origin goods subject to various Section 232 actions. Trade analysts have interpreted the framework as capping pharmaceutical-related tariffs at 15% for qualifying EU exports, though the joint statement itself covers a wider range of goods and does not single out pharmaceuticals by name. If that interpretation holds, companies manufacturing in Germany, Ireland, or Denmark, three of the largest pharmaceutical export hubs in Europe, would operate under a cap that makes the 100% figure largely academic.
This matters because Europe accounts for a substantial share of branded drug imports into the United States. Roche, Sanofi, AstraZeneca, and GSK all maintain major production facilities in EU member states. For these firms, the live question is not whether they face a 100% tariff but whether the 15% cap applies to their products, and whether they can push it even lower by meeting additional onshoring or pricing conditions.
What nobody has answered yet
Several critical gaps remain, and they are big enough to determine whether this policy reshapes the drug market or mostly stays on paper.
First, no public government data shows how many branded drug imports currently qualify for 0% exemptions under existing trade frameworks. The administration has not disclosed which countries beyond the EU have completed, or are close to completing, the bilateral agreements required under Executive Order 14346. Without that information, it is difficult to estimate what share of the U.S. pharmaceutical import market, valued at roughly $200 billion annually based on U.S. Census Bureau trade data for 2025, would actually face the full tariff.
Second, there is an unresolved tension between the EU framework and the proclamation’s escalation schedule. The Commerce Department’s joint statement describes a cap for European goods. The proclamation describes a system where firms without pricing deals eventually face 100%. Whether the EU cap overrides the escalation timeline for European manufacturers, or whether the two mechanisms run on parallel tracks, has not been clarified publicly. The Washington Post characterized the overall structure as an attempt to wield the threat of 100% duties as a negotiating tool, even as many allied nations are functionally shielded by side agreements.
Other open questions are just as consequential. The proclamation invokes national security authority but does not spell out how regulators will decide which drugs or ingredients are “critical” enough to warrant waivers. It does not explain what happens if a company announces a new U.S. plant and then construction timelines slip by years, as large pharmaceutical facilities routinely do. And it says nothing about generics or biosimilars, which fall technically outside the branded-drug scope but could face separate action under related trade authorities.
Congress, for its part, has been largely quiet. A handful of senators from both parties have requested briefings from the U.S. Trade Representative’s office, but no legislation to block or modify the proclamation has been introduced as of early May 2026. The absence of detailed guidance from the executive branch, combined with Congressional inaction, raises the prospect of case-by-case lobbying battles at the agencies that administer trade remedies.
Who actually gets hurt
If the tier system works as designed, the companies most exposed are not the multinational giants with Washington lobbyists on retainer. They are mid-size and specialty drugmakers that lack the resources to negotiate bilateral deals, the capital to build U.S. plants, or the political leverage to secure waivers.
Think of a firm that manufactures a single orphan drug at one facility in India or South Korea, in a country without a completed trade agreement. That company could face the full 100% rate with no realistic path to relief in the near term. For the patients who depend on that drug, the consequences could be direct and painful: higher co-pays, supply disruptions, or both.
For the broader market, the immediate impact hinges on how many suppliers land in the protected tiers. If most major branded drugs enter the U.S. at 0% or under the EU’s reported 15% cap, retail prices may not shift noticeably in the short run. But if negotiations stall, or if exemptions prove narrower than the industry expects, importers will face higher landed costs that ripple through wholesalers, pharmacy benefit managers, and ultimately the price tags patients see at the pharmacy counter.
What to watch as the bilateral deals take shape
The administration has framed this policy as a way to force lower drug prices and more domestic production at the same time. Whether that bet pays off depends on specifics that are still taking shape in May 2026: which countries finalize bilateral agreements, how aggressively regulators grant waivers, and how much leverage drugmakers actually hold when many of their products are medically indispensable and have no substitutes.
Three markers will tell the story over the next several months. The first is whether the U.S. Trade Representative publishes a list of countries with completed agreements, giving the market a clear picture of who is shielded and who is not. The second is whether any major drugmaker publicly announces it will absorb the tariff rather than negotiate, which would signal that the 100% rate has real teeth. The third is whether generic and biosimilar manufacturers get pulled into a parallel action, which would widen the impact far beyond branded drugs.
Until those signals arrive, the 100% tariff functions less as a fixed tax on medicine and more as an opening bid, one where the fine print matters far more than the headline number.
